BST008

This study is an exploratory clinical trial initiated by an open, single arm researcher to evaluate the safety, tolerability, and preliminary efficacy of BST08 in the treatment of advanced non-small cell lung cancer in subjects. This study plans to set up two experimental groups: monotherapy group A: 9x10 ^ 10 BST08 (3 cases) and combination therapy group B: 9x10 ^ 10 BST08+Pabolizhu 200mg Q3W (6 cases).